In: The International Journal of Cardiovascular Imaging, 2015, vol. 31, no. 5, p. 915-926
|
In: Clinical Research in Cardiology, 2015, vol. 104, no. 2, p. 124-135
|
In: Blood, 2020, vol. 137, no. 10, p. 1365–1376
Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B cell receptor immunoglobulins (BcR IG). Patients in certain major stereotyped subsets often display remarkably consistent clinicobiological profiles, suggesting that the study of BcR IG stereotypy in CLL has important implications for understanding disease...
|
In: Value in Health, 2019, vol. 22, no. 12, p. 1355–1361
Elderly patients receive bare metal stents instead of drug-eluting stents (DES) to shorten the duration of dual antiplatelet therapy (DAPT). The SENIOR trial compared outcomes between these 2 types of stents combined with a short duration of DAPT. A significant decrease in the number of patients with at least 1 major adverse cardiac and cerebrovascular event (MACCE) was noted in the DES...
|
In: Cell reports, 2017, vol. 18, no. 2, p. 496-507
The Mre11 complex (Mre11, Rad50, and Nbs1) is integral to both DNA repair and ataxia telangiectasia mutated (ATM)-dependent DNA damage signaling. All three Mre11 complex components are essential for viability at the cellular and organismal levels. To delineate essential and non-essential Mre11 complex functions that are mediated by Nbs1, we used TALEN-based genome editing to derive Nbs1...
|
In: Catheterization and Cardiovascular Interventions, 2019, p. ccd.28376
To evaluate the safety and efficacy outcomes after primary percutaneous coronary intervention (pPCI) with second‐generation Resolute™ zotarolimus‐eluting stent (R‐ ZES) in patients enrolled in the DAPT‐STEMI Trial (NCT01459627).Background: R‐ ZES is one of the most used drug eluting stents worldwide. To date, the safety and efficacy data of this stent in setting of STEMI is...
|
In: Cardiovascular Revascularization Medicine, 2019, vol. 20, no. 7, p. 577–582
Background: The advent of bioresorbable vascular scaffolds (BVS) was considered as a potential improvement in percutaneous coronary intervention (PCI) after the groundbreaking development of drug eluting stents (DES). However, the clinical performance, long-term safety and efficacy of BVS in complex coronary lesions remain uncertain. COMPARE ABSORB, a multicenter, single blind, prospective ...
|
In: JACC: Cardiovascular Interventions, 2018, vol. 11, no. 10, p. 995–1002
ObjectivesThe authors aimed to compare long-term data of an ultrathin cobalt- chromium stent with passive silicon carbide coating and an active biodegradable polymer that releases sirolimus (O-SES) (Orsiro, BIOTRONIK, Bülach, Switzerland) with the durable polymer-based Xience Prime everolimus-eluting stent (X-EES) (Abbott Vascular, Santa Clara, California).BackgroundBiodegradable polymer...
|
In: Sozial- und Präventivmedizin, 2006, vol. 51, no. 1, p. 24-33
|
In: European Radiology, 2008, vol. 18, no. 12, p. 2776-2784
|